MammaPrint: Difference between revisions
CSV import |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | |||
Latest revision as of 12:59, 18 March 2025
MammaPrint is a genomic test that analyzes the activity of certain genes in early-stage breast cancer. MammaPrint uses the science of genomics to measure the activity of 70 genes, providing information that can help doctors make treatment decisions.
Overview[edit]
MammaPrint was developed by Agendia, a leading molecular diagnostics company. It is a 70-gene signature assay and is used to predict the risk of metastasis in breast cancer patients. The test is based on the RNA expression profile of these 70 genes.
Clinical Use[edit]
MammaPrint is used in the clinical setting to help doctors determine the likelihood of breast cancer recurrence and the benefit of chemotherapy. The test can be used for patients with stage 1 or stage 2 breast cancer that is ER-positive or ER-negative, and who have either node-negative or node-positive disease.
Test Results[edit]
MammaPrint test results are reported as either low risk or high risk. A low risk result means that the patient's cancer has a low risk of recurrence, while a high risk result means that the patient's cancer has a high risk of recurrence.
Limitations[edit]
While MammaPrint can provide valuable information, it has limitations. It is not suitable for all patients, and the results should be interpreted in the context of other clinical and pathological factors.
